Literature DB >> 15545625

Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex.

James Brugarolas1, Kui Lei, Rebecca L Hurley, Brendan D Manning, Jan H Reiling, Ernst Hafen, Lee A Witters, Leif W Ellisen, William G Kaelin.   

Abstract

Mammalian target of rapamycin (mTOR) is a central regulator of protein synthesis whose activity is modulated by a variety of signals. Energy depletion and hypoxia result in mTOR inhibition. While energy depletion inhibits mTOR through a process involving the activation of AMP-activated protein kinase (AMPK) by LKB1 and subsequent phosphorylation of TSC2, the mechanism of mTOR inhibition by hypoxia is not known. Here we show that mTOR inhibition by hypoxia requires the TSC1/TSC2 tumor suppressor complex and the hypoxia-inducible gene REDD1/RTP801. Disruption of the TSC1/TSC2 complex through loss of TSC1 or TSC2 blocks the effects of hypoxia on mTOR, as measured by changes in the mTOR targets S6K and 4E-BP1, and results in abnormal accumulation of Hypoxia-inducible factor (HIF). In contrast to energy depletion, mTOR inhibition by hypoxia does not require AMPK or LKB1. Down-regulation of mTOR activity by hypoxia requires de novo mRNA synthesis and correlates with increased expression of the hypoxia-inducible REDD1 gene. Disruption of REDD1 abrogates the hypoxia-induced inhibition of mTOR, and REDD1 overexpression is sufficient to down-regulate S6K phosphorylation in a TSC1/TSC2-dependent manner. Inhibition of mTOR function by hypoxia is likely to be important for tumor suppression as TSC2-deficient cells maintain abnormally high levels of cell proliferation under hypoxia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15545625      PMCID: PMC534650          DOI: 10.1101/gad.1256804

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  54 in total

1.  S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway.

Authors:  Mario Pende; Sung Hee Um; Virginie Mieulet; Melanie Sticker; Valerie L Goss; Jurgen Mestan; Matthias Mueller; Stefano Fumagalli; Sara C Kozma; George Thomas
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

2.  TSC2 mediates cellular energy response to control cell growth and survival.

Authors:  Ken Inoki; Tianqing Zhu; Kun-Liang Guan
Journal:  Cell       Date:  2003-11-26       Impact factor: 41.582

Review 3.  Lymphatics at the crossroads of angiogenesis and lymphangiogenesis.

Authors:  Claudio Scavelli; Elisabetta Weber; Margherita Aglianò; Teresa Cirulli; Beatrice Nico; Angelo Vacca; Domenico Ribatti
Journal:  J Anat       Date:  2004-06       Impact factor: 2.610

4.  Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.

Authors:  Hongbing Zhang; Gregor Cicchetti; Hiroaki Onda; Henry B Koon; Kirsten Asrican; Natalia Bajraszewski; Francisca Vazquez; Christopher L Carpenter; David J Kwiatkowski
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

Review 5.  The AMP-activated protein kinase cascade--a unifying system for energy control.

Authors:  David Carling
Journal:  Trends Biochem Sci       Date:  2004-01       Impact factor: 13.807

Review 6.  Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression.

Authors:  Diane C Fingar; John Blenis
Journal:  Oncogene       Date:  2004-04-19       Impact factor: 9.867

7.  LKB1 is the upstream kinase in the AMP-activated protein kinase cascade.

Authors:  Angela Woods; Stephen R Johnstone; Kristina Dickerson; Fiona C Leiper; Lee G D Fryer; Dietbert Neumann; Uwe Schlattner; Theo Wallimann; Marian Carlson; David Carling
Journal:  Curr Biol       Date:  2003-11-11       Impact factor: 10.834

8.  TSC2 regulates VEGF through mTOR-dependent and -independent pathways.

Authors:  James B Brugarolas; Francisca Vazquez; Archana Reddy; William R Sellers; William G Kaelin
Journal:  Cancer Cell       Date:  2003-08       Impact factor: 31.743

9.  The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila.

Authors:  Jan H Reiling; Ernst Hafen
Journal:  Genes Dev       Date:  2004-11-15       Impact factor: 11.361

10.  The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress.

Authors:  Reuben J Shaw; Monica Kosmatka; Nabeel Bardeesy; Rebecca L Hurley; Lee A Witters; Ronald A DePinho; Lewis C Cantley
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-25       Impact factor: 11.205

View more
  571 in total

1.  Escherichia coli succinic thiolinase. Stoichiometry of phosphorylation and coenzyme A binding.

Authors:  C M Bowman; J S Nishimura
Journal:  J Biol Chem       Date:  1975-07-25       Impact factor: 5.157

Review 2.  Tumor hypoxia and genetic alterations in sporadic cancers.

Authors:  Minoru Koi; Clement R Boland
Journal:  J Obstet Gynaecol Res       Date:  2011-01-27       Impact factor: 1.730

3.  mTOR activity under hypoxia.

Authors:  Douangsone D Vadysirisack; Leif W Ellisen
Journal:  Methods Mol Biol       Date:  2012

Review 4.  Stress responses affecting homeostasis of the alveolar capillary unit.

Authors:  Rubin M Tuder; Toshinori Yoshida
Journal:  Proc Am Thorac Soc       Date:  2011-11

Review 5.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

6.  Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence.

Authors:  Marina Kolesnichenko; Lixin Hong; Rong Liao; Peter K Vogt; Peiqing Sun
Journal:  Cell Cycle       Date:  2012-06-15       Impact factor: 4.534

Review 7.  Rapamycin-resistant effector T-cell therapy.

Authors:  Daniel H Fowler
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 8.  Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis.

Authors:  L Ouyang; Z Shi; S Zhao; F-T Wang; T-T Zhou; B Liu; J-K Bao
Journal:  Cell Prolif       Date:  2012-10-03       Impact factor: 6.831

9.  Activation of the AKT and mammalian target of rapamycin pathways and the inhibitory effects of rapamycin on those pathways in canine malignant melanoma cell lines.

Authors:  Michael S Kent; Cameron J Collins; Fang Ye
Journal:  Am J Vet Res       Date:  2009-02       Impact factor: 1.156

10.  Curcumin ameliorates the neurodegenerative pathology in A53T α-synuclein cell model of Parkinson's disease through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy.

Authors:  Tian-Fang Jiang; Ying-Jie Zhang; Hai-Yan Zhou; Hong-Mei Wang; Li-Peng Tian; Jun Liu; Jian-Qing Ding; Sheng-Di Chen
Journal:  J Neuroimmune Pharmacol       Date:  2013-01-17       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.